Explore

Trendline Trendline
Chiesi Acquires KalVista for $1.9 Billion, Expanding Rare Disease Portfolio

Chiesi Acquires KalVista for $1.9 Billion, Expanding Rare Disease Portfolio

Chiesi Acquires KalVista for $1.9 Billion, Expanding Rare Disease Portfolio
Trendline Trendline
AstraZeneca Restructures Pipeline, Focuses on Cancer and Rare Diseases

AstraZeneca Restructures Pipeline, Focuses on Cancer and Rare Diseases

AstraZeneca Restructures Pipeline, Focuses on Cancer and Rare Diseases
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Veradermics Prices Upsized Public Offering and Private Placement to Fund Hair Loss Therapeutics

Veradermics Prices Upsized Public Offering and Private Placement to Fund Hair Loss Therapeutics

Veradermics Prices Upsized Public Offering and Private Placement to Fund Hair Loss Therapeutics
Trendline Trendline
Chiesi Acquires KalVista for $1.9B, Expanding Rare Disease Portfolio

Chiesi Acquires KalVista for $1.9B, Expanding Rare Disease Portfolio

Chiesi Acquires KalVista for $1.9B, Expanding Rare Disease Portfolio
Trendline Trendline
Organon Cancels Q1 2026 Earnings Call Amid Acquisition by Sun Pharmaceutical

Organon Cancels Q1 2026 Earnings Call Amid Acquisition by Sun Pharmaceutical

Organon Cancels Q1 2026 Earnings Call Amid Acquisition by Sun Pharmaceutical
Trendline Trendline
Two Harbors Investment Corp. Announces Merger Agreement with CrossCountry Mortgage

Two Harbors Investment Corp. Announces Merger Agreement with CrossCountry Mortgage

Two Harbors Investment Corp. Announces Merger Agreement with CrossCountry Mortgage
Trendline Trendline
CareDx Acquires Naveris to Expand into HPV-Driven Cancer Monitoring

CareDx Acquires Naveris to Expand into HPV-Driven Cancer Monitoring

CareDx Acquires Naveris to Expand into HPV-Driven Cancer Monitoring
Trendline Trendline
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding Rare Disease Portfolio

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding Rare Disease Portfolio

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding Rare Disease Portfolio
Trendline Trendline
Organon Cancels Earnings Call Amid Acquisition by Sun Pharmaceutical

Organon Cancels Earnings Call Amid Acquisition by Sun Pharmaceutical

Organon Cancels Earnings Call Amid Acquisition by Sun Pharmaceutical
Trendline Trendline
Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback

Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback

Soligenix's Phase 3 Trial for HyBryte in CTCL Treatment Faces Setback
Trendline Trendline
Teva Pharmaceuticals Acquires Emalex Biosciences in $900 Million Deal

Teva Pharmaceuticals Acquires Emalex Biosciences in $900 Million Deal

Teva Pharmaceuticals Acquires Emalex Biosciences in $900 Million Deal